BioCentury | Dec 12, 2018
Distillery Therapeutics

Neurology

...disease (AD); frontotemporal dementia; progressive supranuclear palsy (PSP) Patient sample and mouse studies suggest inhibiting LGMN-mediated...
...and PSP. In brain tissue samples from patients with AD, FTD or PSP, levels of LGMN...
...steps could include developing a small molecule that blocks the LGMN-SRPK2 interaction. TARGET/MARKER/PATHWAY: Legumain (LGMN; AEP...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Neurology

...INDICATION: Parkinson's disease (PD) Patient sample and mouse studies suggest inhibiting LGMN could help treat PD...
...tissue samples from PD and Lewy body dementia patients, levels of asparagine 103 α-synuclein, an LGMN-mediated...
...testing a small molecular inhibitor of LGMN in other models of PD. TARGET/MARKER/PATHWAY: Legumain (LGMN; AEP...
BioCentury | Jan 14, 2016
Targets & Mechanisms

Moot point in AD

...Medicine, Atlanta, Ga. TauRx Pharmaceuticals Ltd., Singapore Targets and Compounds AEP ( LGMN ) - Legumain...
...The other 47 compounds target only one of the two pathways.AEP ( LGMN ) - Legumain...
...from endolysosomal compartments into the cytosol, where it cleaves cytosolic tau.AEP ( LGMN ) - Legumain...
BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: Legumain (LGMN; AEP)

...vitro, patient sample and mouse studies suggest inhibiting LGMN could help treat AD. Levels of LGMN...
...tissue samples from AD patients than from healthy controls. In a mouse model of AD, LGMN...
...of LGMN. Next steps include synthesizing a small molecule inhibitor of LGMN. TARGET/MARKER/PATHWAY: Legumain (LGMN; AEP...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Legumain (LGMN; AEP...
...AEP); microtubule-associated protein-t (MAPT; tau; FTDP-17) In vitro, patient sample and mouse studies suggest inhibiting AEP...
...assays showed that AEP cleaved human tau into neurotoxic fragments. In the mouse AD model, Aep...
BioCentury | May 30, 2013
Distillery Therapeutics

Indication: Neurology

...suggest inhibiting AEP could help treat AD. In homogenates derived from patient frontal cortex samples, AEP...
...was greater than that in samples from healthy controls. In rat hippocampal slices, acidosis activated AEP...
...FTDP-17) hyperphosphorylation, a hallmark of AD. In a human neuronal cell line, small interfering RNA-mediated AEP...
BioCentury | Jan 10, 2013
Distillery Techniques

Technology: Imaging

...of legumain (LGMN) An activity-based fluorescent probe could be used to study the activity of LGMN...
...of LGMN. In human monocyte and cancer cell lines, the probe identified different patterns of LGMN...
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer O6-methylguanine DNA methyltransferase (MGMT) A cell culture study suggests that meta aminomethyl-substituted O6-benzylguanine (BG) may be useful for overcoming the resistance...
BioCentury | Apr 10, 2008
Distillery Therapeutics

This Week in Therapeutics

...information Neurology Ischemia Asparagine endopeptidase (AEP) In vitro and in vivo studies suggest that inhibiting AEP...
...for treating neurodegeneration triggered by stroke or ischemia. Under acidic conditions typical of cerebral ischemia, AEP...
...AEP. That, in turn, lowered neuronal cell death. Next steps could include identifying inhibitors of AEP...
BioCentury | Jul 24, 2006
Company News

AtheroGenics board of directors update

...president and CEO of Clearview Projects Inc.; and Margaret Grayson, EVP and general manager of AEP...
Items per page:
1 - 10 of 10